115 related articles for article (PubMed ID: 10547563)
1. The National Cancer Data base Report on increased use of brachytherapy for the treatment of patients with prostate carcinoma in the U.S.
Mettlin CJ; Murphy GP; McDonald CJ; Menck HR
Cancer; 1999 Nov; 86(9):1877-82. PubMed ID: 10547563
[TBL] [Abstract][Full Text] [Related]
2. The National Cancer Data Base report on race, age, and region variations in prostate cancer treatment.
Mettlin CJ; Murphy GP; Cunningham MP; Menck HR
Cancer; 1997 Oct; 80(7):1261-6. PubMed ID: 9317177
[TBL] [Abstract][Full Text] [Related]
3. The National Cancer Data Base report on longitudinal observations on prostate cancer.
Mettlin CJ; Murphy GP; Ho R; Menck HR
Cancer; 1996 May; 77(10):2162-6. PubMed ID: 8640686
[TBL] [Abstract][Full Text] [Related]
4. A nationwide charge comparison of the principal treatments for early stage prostate carcinoma.
Brandeis J; Pashos CL; Henning JM; Litwin MS
Cancer; 2000 Oct; 89(8):1792-9. PubMed ID: 11042575
[TBL] [Abstract][Full Text] [Related]
5. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
6. Prostate brachytherapy: a descriptive analysis from CaPSURE.
Lee WR; Sharkey J; Cowan JE; DuChane J; Carroll PR;
Brachytherapy; 2007; 6(2):123-8. PubMed ID: 17434105
[TBL] [Abstract][Full Text] [Related]
7. The 1999 patterns of care study of radiotherapy in localized prostate carcinoma: a comprehensive survey of prostate brachytherapy in the United States.
Lee WR; Moughan J; Owen JB; Zelefsky MJ
Cancer; 2003 Nov; 98(9):1987-94. PubMed ID: 14584083
[TBL] [Abstract][Full Text] [Related]
8. Prostate carcinoma presentation, diagnosis, and staging: an update form the National Cancer Data Base.
Miller DC; Hafez KS; Stewart A; Montie JE; Wei JT
Cancer; 2003 Sep; 98(6):1169-78. PubMed ID: 12973840
[TBL] [Abstract][Full Text] [Related]
9. Alternative medicine use in patients with localized prostate carcinoma treated with curative intent.
Lippert MC; McClain R; Boyd JC; Theodorescu D
Cancer; 1999 Dec; 86(12):2642-8. PubMed ID: 10594859
[TBL] [Abstract][Full Text] [Related]
10. The National Cancer Data Base report on patterns of care for testicular carcinoma, 1985-1996.
Steele GS; Richie JP; Stewart AK; Menck HR
Cancer; 1999 Nov; 86(10):2171-83. PubMed ID: 10570449
[TBL] [Abstract][Full Text] [Related]
11. Changing trends in national practice for external beam radiotherapy for clinically localized prostate cancer: 1999 Patterns of Care survey for prostate cancer.
Zelefsky MJ; Moughan J; Owen J; Zietman AL; Roach M; Hanks GE
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):1053-61. PubMed ID: 15234039
[TBL] [Abstract][Full Text] [Related]
12. A comprehensive and novel predictive modeling technique using detailed pathology factors in men with localized prostate carcinoma.
Potters L; Purrazzella R; Brustein S; Fearn P; Leibel SA; Kattan MW
Cancer; 2002 Oct; 95(7):1451-6. PubMed ID: 12237913
[TBL] [Abstract][Full Text] [Related]
13. Impact of brachytherapy on regional, racial, marital status, and age-related patterns of definitive treatment for clinically localized prostate carcinoma.
Copeland LA; Elshaikh MA; Jackson J; Penner LA; Underwood W
Cancer; 2005 Oct; 104(7):1372-80. PubMed ID: 16118801
[TBL] [Abstract][Full Text] [Related]
14. Body mass index and prostate-specific antigen failure following brachytherapy for localized prostate cancer.
Efstathiou JA; Skowronski RY; Coen JJ; Grocela JA; Hirsch AE; Zietman AL
Int J Radiat Oncol Biol Phys; 2008 Aug; 71(5):1302-8. PubMed ID: 18262732
[TBL] [Abstract][Full Text] [Related]
15. Bowel function and bother after treatment for early stage prostate cancer: a longitudinal quality of life analysis from CaPSURE.
Litwin MS; Sadetsky N; Pasta DJ; Lubeck DP
J Urol; 2004 Aug; 172(2):515-9. PubMed ID: 15247718
[TBL] [Abstract][Full Text] [Related]
16. Predictors of secondary cancer treatment in patients receiving local therapy for prostate cancer: data from cancer of the prostate strategic urologic research endeavor.
Grossfeld GD; Li YP; Lubeck DP; Broering JM; Mehta SS; Carroll PR
J Urol; 2002 Aug; 168(2):530-5. PubMed ID: 12131303
[TBL] [Abstract][Full Text] [Related]
17. Brachytherapy for clinically localized prostate cancer: thirteen-year disease-free survival of 769 consecutive prostate cancer patients treated with permanent implants alone.
Ragde H; Grado GL; Nadir BS
Arch Esp Urol; 2001 Sep; 54(7):739-47. PubMed ID: 11692443
[TBL] [Abstract][Full Text] [Related]
18. Prediagnosis prostate specific antigen velocity is associated with risk of prostate cancer progression following brachytherapy and external beam radiation therapy.
Eggener SE; Roehl KA; Yossepowitch O; Catalona WJ
J Urol; 2006 Oct; 176(4 Pt 1):1399-403. PubMed ID: 16952643
[TBL] [Abstract][Full Text] [Related]
19. Three-year results of treatment for prostate cancer with low-dose rate temporary iridium-192 brachytherapy.
Momma T; Saito S; Toya K; Yorozu A; Dokiya T; Murai M
Int J Urol; 2006 Mar; 13(3):218-23. PubMed ID: 16643612
[TBL] [Abstract][Full Text] [Related]
20. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Katoh H; Noda SE; Ito K; Yamamoto T; Kashiwagi B; Nakano T
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):472-8. PubMed ID: 16168839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
